AAP
IMVT icon

Arax Advisory Partners’s Immunovant IMVT Stock Holding History

Arax Advisory Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3K Buy
+398
New +$12.1K ﹤0.01% 4118
2026
Q1 		– Sell
-102
Closed -$2.59K – 4061
2025
Q4 		$2.59K Sell
102
-56
-35% -$1.25K ﹤0.01% 3167
2025
Q3 		$2.55K Buy
+158
New +$2.56K ﹤0.01% 3054

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Arax Advisory Partners's IMVT Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Immunovant (IMVT) in Q2 2026: 398 shares worth $15.3K. The stake represents ﹤0.01% of the portfolio and ranks #4118 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in IMVT as recently as Q4 2025.

Arax Advisory Partners first reported a position in IMVT in Q3 2025 and has held it in 3 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Arax Advisory Partners held 398 shares of Immunovant worth $15.3K as of Q2 2026.
  • Immunovant was a new Arax Advisory Partners position in Q2 2026.
  • Immunovant made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4118 holding.
  • Arax Advisory Partners first reported a position in Immunovant in Q3 2025 and has held it in 3 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.